Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-labelled, prospective 96-week study comparing the antiviral
efficacy and safety of switching to entecavir 1 mg QD from lamivudine versus maintaining
lamivudine 100 mg QD treatment in HBV-infected subjects currently receiving lamivudine
monotherapy.